UPB — Upstream Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2022626 ·
Last close
$5.30
Market Cap
$290.29M
52W High
$33.68
52W Low
$4.99
ADV30
589,190
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 773,000 | — | -42,368,000 | -39,702,000 | 281,171,000 | 79,397,000 | 10,214,000 |
| Mar 2026 | 1,034,000 | — | -43,615,000 | -40,591,000 | 318,054,000 | 96,724,000 | 14,059,000 |
| Dec 2025 | 668,000 | — | -46,167,000 | -42,459,000 | 353,772,000 | 101,578,000 | 14,001,000 |
| Sep 2025 | 683,000 | — | -37,834,000 | -33,748,000 | 391,195,000 | 72,164,000 | 12,611,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-139,962,000
Investing CF
$162,301,000
Financing CF
$3,073,000
CapEx
$-303,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.90
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-374,814,000
Inventory
—
Receivables
$2,607,000
ST Investments
$197,855,000
EBIT TTM
$-171,963,000
Pretax Income TTM
$-156,764,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,158,000
EBITDA
$-169,782,000
Free Cash Flow
$-86,616,000
Enterprise Value
$53,485,064
Total Cash
$261,307,008
Total Debt
$954,000
Shares Out
54,771,041
Trailing EPS
$-2.88
Book Value
$5.59
ROE
-46.1%
ROA
-30.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,854,000 | -160,361,000 | -143,443,000 | 353,772,000 | 14,001,000 | 339,771,000 | -133,275,000 |
| Dec 2024 | 2,370,000 | -77,764,000 | -62,806,000 | 481,719,000 | 11,867,000 | 469,852,000 | -59,172,000 |
| Dec 2023 | 2,380,000 | -40,114,000 | -20,537,000 | 117,198,000 | 240,324,000 | -123,126,000 | -37,926,000 |
| Dec 2022 | 1,212,000 | -23,909,000 | -23,868,000 | 18,478,000 | 124,633,000 | -106,155,000 | -19,021,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.80
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $5.30 · call volume: 6 · put volume: 14Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYDY | CytoDyn Inc. | $290.76M | $0.21 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $286.51M | $2.61 | — |
| LAB | STANDARD BIOTOOLS INC. | $285.52M | $0.73 | — |
| CATX | Perspective Therapeutics, Inc. | $285.38M | $2.50 | — |
| FULC | Fulcrum Therapeutics, Inc. | $283.83M | $3.72 | — |
News headlines (Yahoo Finance, 1h cache)
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
2026-09-08 07:30 · Yahoo
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
2026-09-01 11:31 · Yahoo
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
2026-08-11 11:00 · Yahoo
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-14 16:00 · Yahoo
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?
2026-06-23 15:36 · Yahoo
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E
2026-06-14 14:00 · Yahoo
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-03 11:00 · Yahoo
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International
2026-05-18 15:30 · Yahoo
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 11:00 · Yahoo
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
2026-05-13 12:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.